- Home
- MESO vs VRNT Comparison
MESO vs VRNT Comparison
Compare MESO & VRNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- VRNT
- Stock Information
- Founded
- MESO 2004
- VRNT 1994
- Country
- MESO Australia
- VRNT United States
- Employees
- MESO 81
- VRNT N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- VRNT EDP Services
- Sector
- MESO Health Care
- VRNT Technology
- Exchange
- MESO Nasdaq
- VRNT Nasdaq
- Market Cap
- MESO 2.0B
- VRNT 1.2B
- IPO Year
- MESO N/A
- VRNT N/A
- Fundamental
- Price
- MESO $15.60
- VRNT $20.28
- Analyst Decision
- MESO Buy
- VRNT Hold
- Analyst Count
- MESO 2
- VRNT 6
- Target Price
- MESO $24.00
- VRNT $25.60
- AVG Volume (30 Days)
- MESO 213.4K
- VRNT 1.4M
- Earning Date
- MESO 08-28-2025
- VRNT 12-03-2025
- Dividend Yield
- MESO N/A
- VRNT N/A
- EPS Growth
- MESO N/A
- VRNT 10.62
- EPS
- MESO N/A
- VRNT 0.74
- Revenue
- MESO $17,198,000.00
- VRNT $893,843,000.00
- Revenue This Year
- MESO $288.50
- VRNT $7.73
- Revenue Next Year
- MESO $167.17
- VRNT $5.67
- P/E Ratio
- MESO N/A
- VRNT $27.51
- Revenue Growth
- MESO 191.39
- VRNT N/A
- 52 Week Low
- MESO $8.34
- VRNT $14.15
- 52 Week High
- MESO $22.00
- VRNT $34.80
- Technical
- Relative Strength Index (RSI)
- MESO 39.64
- VRNT 50.97
- Support Level
- MESO $16.10
- VRNT $20.23
- Resistance Level
- MESO $16.91
- VRNT $20.31
- Average True Range (ATR)
- MESO 0.50
- VRNT 0.04
- MACD
- MESO -0.27
- VRNT 0.00
- Stochastic Oscillator
- MESO 0.60
- VRNT 56.25
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About VRNT Verint Systems Inc.
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.